Facebook Follow AMS on Linkedin Follow us on Twitter @amsCoolAgain AMS on Instagram

Estradot and Estalis to remain on the PBS

13 September 2021

Back in May, Sandoz, the supplier of Estradot and Estalis applied to delist these medications from the Pharmaceuticals Benefits Scheme (PBS) as they were not financially viable. The AMS in collaboration with the Royal Australian and New Zealand College of Obstetricians and Gynaeocologists (RANZCOG) and the Endocrine Society of Australia (ESA) wrote to Minister Hunt expressing our concern about access to Estradot and Estalis and the potential health outcomes if these medications were to be delisted from the PBS.

Following further discussions, Sandoz agreed to apply to the Pharmaceutical Benefits Advisory Committee (PBAC) for a price increase instead of delisting Estradot and Estalis from the PBS. Again, in collaboration with RANZCOG and ESA, AMS wrote a joint letter of support to PBAC for a price increase, rather than them being delisted from the PBS.

AMS is now happy to advise that the PBAC has agreed to the price increase for Estradot and Estalis from 1 October. This price increase means that these medications will remain on the PBS and support continuous and sustainable supply to the Australian market. While many women will need to pay more for these medications from 1 October, importantly, women on a healthcare card will only need to pay the concession price. A letter from Sandoz is attached for further information.

pdfHCP Letter Estradot Estalis Sep 2021

Print Email

Shortage of PROGYNOVA estradiol valerate addressed with SSSI

12 August 2021

Information for Doctors

The Therapeutic Goods Administration (TGA) is advising health professionals and consumers of a current shortage for all strengths of PROGYNOVA estradiol valerate tablets. Due to manufacturing issues the shortage is expected to continue until May 2022.

PROGYNOVA tablets are used for short-term relief of symptoms associated with menopause.

The TGA has made a Serious Scarcity Substitution Instrument (SSSI) to assist patients in accessing their medicine from their pharmacist without delay, ensure treatments are not interrupted and relieve workload pressure on prescribers and pharmacists.

The SSSI is in force from 13 August 2021 until 1 May 2022. The TGA may, however, revoke the SSSI before its end date if the serious scarcity is resolved, or safety concerns are identified.

For more information see Substitution instrument to address shortage of PROGYNOVA estradiol valerate tablets (multiple strengths)

You should be alert to the current shortage of Progynova tablets when prescribing to your patients. Consider prescribing available estradiol-only tablets such as Estrofem and Zumenon tablet.

Zumenon is PBS-listed when prescribed but Estrofem is not.

Information for patients

Talk to your doctor or pharmacist if you have any questions regarding this substitution.

The pack size of estradiol-only tablets varies between brands. However, your pharmacist will supply the correct total dose that your doctor has prescribed.

If you have been prescribed Progynova 1mg or 2mg tablets and you receive a substitute medicine, your pharmacist will explain to you how to take your tablets.

If you are provided 2 mg tablets as a substitute for your usual 1 mg tablets, ask your pharmacist for advice on how to cut the tablets. If someone else is cutting the tablets for you, they may need to consider using personal protective equipment such as gloves and a mask to avoid unintended exposure to estradiol. Low dose of unintended exposure may cause harm or pose a risk of harm.

Continue Reading

Print Email

Menopausal Hormone Therapy and Non-Hormonal Options Shortages in Australia – Update 23 June 2021

There has been a recent shortage of a number of menopausal hormone therapy (MHT) preparations and some of these have now been or soon will be resolved:

Oral MHT

Duavive – supply due to be resolved by end January 2022

Progynova 2mg – supply due to be resolved by end of April 2022

Femonston Conti – supply shortage expected between 25 June and 9 July

 

Transdermal MHT

Estradot 100 – supply due to be resolved by 31 August

Estradot 75 – supply due to be resolved by 31 August

Estradot 50 – supply due to be resolved by 1 July

Estradot 37.5 – supply due to be resolved by 31 August

Estradot 25 – supply due to be resolved by 1 July

Estalis Conti 50/140 – supply resolved

Estalis Conti 50/250 – supply resolved

Estalis Sequi 50/140 – supply resolved

Estalis Sequi 50/250 – supply resolved

Estraderm MX 50 – supply resolved

Estraderm MX 100 - supply resolved

Non-Hormonal Options

There is also an expected shortage of supply of non-hormonal treatment options:

Gabapentin-APOTEX 100mg – supply shortage expected between 20 August- 15 October

Gabapentin 300mg- supply shortage expected between 18 June- 16 July

APX-Gabapentin 300mg- supply shortage expected between 16 July- 6 August

Gabapentin-APOTEX 300mg – to be discontinued from 18 July

Combined oral contraceptive pill

There is also an expected shortage of combined oral contraceptive pill:

Qliara – supply due to be resolved by 1 June 2022

Please note that dates for supply have been sourced from either the pharmaceutical supplier or the TGA website and may change at any time.

Continue Reading

Print Email

Menopausal Hormone Therapy Shortages in Australia – Update 22 February 2021

There has been a recent shortage of a number of menopausal hormone therapy (MHT) preparations and some of these have now been or soon will be resolved:

Oral MHT

Duavive – supply due to be resolved by end January 2022 

Transdermal

Estradot 100 – supply due to be resolved by the end of March

Estradot 75 – supply due to be resolved by the end of April

Estradot 50 – supply due to be resolved by the end of March

Estradot 37.5 – supply due to be resolved by the end of March

Estradot 25 – supply due to be resolved by the end of April

Estalis Conti 50/140 - supply due to be resolved by early April

Estalis Conti 50/250 - supply due to be resolved by early April

Estalis Sequi 50/140 – supply due to be resolved by early May

Estalis Sequi 50/250 – supply due to be resolved by early May

Estraderm MX 50 – supply due to be resolved by end of April

Estraderm MX 100 - supply due to be resolved by end of April

Please note that dates for supply have been sourced from either the pharmaceutical supplier or the TGA website and may change at any time.

Continue Reading

Print Email

Australia Day Honours 2021 – Professor Susan Davis AO

AMS would like to congratulate AMS and IMS Past-President Professor Susan Davis on being awarded an Officer (AO) in the General Division for distinguished service of a high degree to Australia or humanity at large.

Sue was awarded the Australia Day Honour for distinguished service to medicine, to women's health as a clinical endocrinologist and researcher, and to medical education.

Many of you would know how tirelessly Sue has worked in women’s health and particularly in menopause education and research.

Congratulation Sue on your award, which is most deserving.

Print Email

Menopausal Hormone Therapy Shortages in Australia – Update 27 January 2021

There has been a recent shortage of a number of menopausal hormone therapy (MHT) preparations and some of these have now been or soon will be resolved:

Oral MHT

Femoston 1/10 – resolved

Duavive – supply due to be resolved by end January 2022

Angeliq - resolved 

Transdermal

Climara – resolved

Estradot 100 – resolved

Estradot 75 – supply due to be resolved by the early April

Estradot 50 – supply due to be resolved by the early February

Estradot 37.5 – supply due to be resolved by early April

Estradot 25 – resolved

Estalis Conti - resolved

Estalis Sequi 50/140 –supply due to be resolved by mid February

Estalis Sequi 50/250 –supply due to be resolved by mid February

Estraderm MX 50 – supply due to be resolved by end of April

Estraderm MX 100 - supply due to be resolved by end of April 

Estrogel/Estrogel Pro – resolved

Please note that dates for supply have been sourced from either the pharmaceutical distributor or the TGA website and may change at any time.

Continue Reading

Print Email

Menopausal Hormone Therapy Shortages in Australia - Update 9 December 2020

There has been a recent shortage of a number of menopausal hormone therapy (MHT) preparations and some of these have now been or soon will be resolved:

Oral MHT

Femoston 1/10 – resolved

Duavive – supply due to be resolved by April 2021

Angeliq - resolved 

Transdermal

Climara – resolved

Estradot 100 – resolved

Estradot 75 – supply due to be resolved by the end of December

Estradot 50 – supply due to be resolved by the end of December

Estradot 37.5 – resolved

Estradot 25 – supply due to be resolved by the end of December

Estalis Conti - supply due to be resolved by end of December

Estalis Sequi –supply due to be resolved by March 2021

Estrogel/Estrogel Pro 

Estrogel/Estrogel Pro - resolved

Continue Reading

Print Email

Early Menopause Webinars – 3 Part Series

Want to Know more about Early Menopause?

Early menopause changes you. You physically have changed. You emotionally change. You psychologically change.

Join a panel of leading experts and women with lived experience of early menopause with an opportunity to ask your questions.

EM Webinars for women 2020

Healthtalk Australia

Click on links below to register:

19 October 2020, 2:30 pm – Spontaneous Early Menopause

16 November 2020, 10:00 am – Early Menopause associated with gynecological cancer

30 November 2020, 10:30 am - Early Menopause associated with breast cancer

Even if you can’t join live, register now and we’ll send you the recorded webcast to watch at your convenience.

For further information please email: This email address is being protected from spambots. You need JavaScript enabled to view it. 

pdfEarly Menopause Webinars – 3 Part Series Flyer235.64 KB

 EM sponsors

Continue Reading

Print Email

A Current Affair - Linking Menopausal Hormone Therapy (MHT) and Breast Cancer

On 23 September, A Current Affair screened a segment featuring Blanche D’Alpuget (the late Bob Hawke’s wife) which may raise some concerns for your patients. In the segment she discusses how she was diagnosed with breast cancer after her MHT dosage was increased. Dr Kerryn Phelps was also interviewed and claimed that the recent evidence shows that MHT ‘triples’ the risk of breast cancer.

Dr Phelps references the Lancet study published in August last year.

We refer you to the excellent paper written by Professor Susan Davis, President, International Menopause Society and AMS Past-President in response to the Lancet paper, to assist you in discussion about the risks and benefits with your patients.

www.menopause.org.au/hp/gp-hp-resources/1483-menopause-matters

We also refer you to our Fact Sheet and Infographic on “What is MHT and is it safe?” which is a good resource for your patients.

www.menopause.org.au/health-info/fact-sheets/what-is-menopausal-hormone-therapy-mht-and-is-it-safe

www.menopause.org.au/health-info/infographics/what-is-menopausal-hormone-therapy-and-is-it-safe

Continue Reading

Print Email

iCARE Covid-19 International Survey 4

covid surveyFor the past few months, people have been feeling the impacts of COVID-19 on their daily lives. 
 
Help us understand those impacts and make a real change by completing and sharing our iCARE survey in your networks.

Survey 4: mbmc-cmcm.ca/covid19

We are releasing monthly versions of the survey. We invite you to fill out each version as it becomes available and to share it in your networks, whether you have filled previous versions or this is your first participation. Each time you fill or share the survey, it will allow us to follow the evolution of COVID-19’s effects on communities worldwide. 

More than 60 000 people from 140 countries have completed the survey (available in multiple languages), and we are still going! 

Take the survey

Preliminary results are now available at: mbmc-cmcm.ca/covid19/stats-wave1 (keep checking the website for results updates as they come in!). Thanks to your participation, we have learned what people think of government public health policies and COVID-19-related restrictions, and how people are coping with the pandemic.

Continue Reading

Print Email

Search

Facebook Follow AMS on Linkedin Follow us on Twitter @amsCoolAgainAMS on Instagram